Skip to content

Study · Non-randomized trial · n = 12 · 1990

2 results

Efficacy of intranasal human calcitonin in patients with Paget's disease refractory to salmon calcitonin.

Muff R, Dambacher MA, Perrenoud A, Simon C, Fischer JA

The American journal of medicine1 Aug 1990Cited by 13 (Europe PMC)

PMID2382666 (opens in a new tab)DOI10.1016/0002-9343(90)90297-q (opens in a new tab)PepBankPUB-02382666
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Paget's disease, salmon calcitonin lowered serum calcium by 2.86%, less effectively than human calcitonin.

    In plain wordsIn Paget's disease, nasal salmon calcitonin lowered blood calcium less effectively than nasal human calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseSerum calcium response
    Study

    n = 12

    Comparator
    3 mg intranasal human calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.1 mg · intranasalAs given in this study (human).

    Measurements

    Serum calcium change
    −2.86%
    0.1 mg intranasal salmon calcitonin
    Standard error
    0.76%
    0.1 mg intranasal salmon calcitonin
    P value
    < 0.05
    0.1 mg sCT versus 3 mg hCT

    Source sentences

    Summary
    Intranasal sCT (0.1 mg) lowered serum calcium less effectively (-2.86 +/- 0.76%) than 3 mg intranasal hCT (p less than 0.05).
    2 context sentences
    Summary · context
    Twelve patients with Paget's disease were treated twice daily for 6 months with 1 mg synthetic hCT administered intranasally.
    Summary · context
    The hypocalcemic effect of 3 mg hCT was compared to that of 0.1 mg sCT before and after the intranasal hCT therapy.
  2. 02HumanNon-randomized trialEfficacy outcome

    In Paget's disease, low-titer antibodies to salmon calcitonin did not affect its hypocalcemic response.

    In plain wordsIn Paget's disease, low-titer antibodies did not affect the blood calcium response to salmon calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeCalcium response by antibody status
    Study

    n: not reported in source

    Comparator
    Patients without low-titer antibodies
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.1 mg · intranasalAs given in this study (human).

    Source sentences

    Summary
    The presence of low-titer antibodies to sCT did not affect the hypocalcemic response to sCT or hCT.
    2 context sentences
    Summary · context
    Twelve patients with Paget's disease were treated twice daily for 6 months with 1 mg synthetic hCT administered intranasally.
    Summary · context
    The hypocalcemic effect of 3 mg hCT was compared to that of 0.1 mg sCT before and after the intranasal hCT therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.